CapsoVision, Inc
CapsoVision, Inc. develops and commercializes capsule endoscopy solutions for gastrointestinal diagnosis, centered on its CapsoCam line of ingestible imaging capsules. The company combines disposable capsule hardware with software and cloud-based viewing workflows, including CapsoView and CapsoCloud, to help clinicians capture and review GI-tract videos. Its revenue comes from product sales, reading services, and software-as-a-service delivery options, with sales tied primarily to the number of capsules sold. CapsoVision is still in an investment phase, funding product development, regulatory work, and commercial expansion while continuing to report operating losses.
Fiscal year 2025 · change from previous year
Development 2024–2025
Business
Share of revenueIngestible imaging capsules sold for GI-tract diagnostic procedures.
CapsoCloud and CapsoView tools used to upload, access, and review capsule videos.
Physician or service-center review of capsule videos and generation of reports.
Customers
CapsoVision sells primarily to medical practices, clinics, hospitals, and physician groups that use capsule endoscopy to evaluate gastrointestinal conditions. A portion of its revenue is routed through group purchasing organizations, which act as procurement agents for underlying healthcare members. The company also serves U.S. government-related healthcare customers, including Department of Defense and Veterans Administration-associated hospitals, which require additional IT security controls for cloud delivery. International customers matter as well because CapsoCloud must be adapted to local privacy and security rules in different countries.
Buy CapsoCam capsules and associated viewing workflows to diagnose GI-tract conditions in clinical settings.
Purchase capsule devices and reading services for outpatient GI diagnostics and patient throughput.
Use the video interpretation service and software tools to review capsule footage and produce reports.
Buy through group purchasing organizations that negotiate procurement for member practices and hospitals.
Adopt CapsoCloud and capsule workflows when the company can meet stricter IT security requirements.
Strategy
CapsoVision is focused on expanding adoption of its GI-tract capsule endoscopy platform across new indications, patient populations, and clinical use cases. A major priority is obtaining and maintaining regulatory clearances, including 510(k) clearance for CapsoCam Colon and AI-enabled capsule products, because commercialization depends on regulatory access. The company is also trying to scale sales through its global sales team, distributors, and marketing efforts while improving reimbursement support from Medicare and other payors. At the same time, it must strengthen supply chain resilience, secure backup suppliers for critical components, and manage the capital needs of a business that is still generating losses.
Commercial growth depends on securing clearances for CapsoCam Colon and AI-enabled capsules.
The business needs broader physician and hospital adoption to increase capsule volumes and service usage.
Single-source and Asia-based suppliers create concentration risk that can disrupt product availability.
Ongoing losses and cash burn require access to external financing to support operations and growth.
Geography
CapsoVision is a U.S.-based company, but its operating footprint is international because its cloud offering must comply with country-specific privacy and security rules outside the United States. Manufacturing and assembly depend heavily on Asia, especially Taiwan and Japan, where the company sources critical components and works with assembly manufacturers. The company also highlighted exposure to U.S. trade policy changes, including tariffs, which can affect product cost and gross margin. This geographic structure makes the business sensitive to cross-border logistics, regulatory compliance, and supply chain continuity.
Risks
CapsoVision faces the classic risks of an early commercial medtech company: regulatory dependence, reimbursement uncertainty, and continued operating losses. Its capsule products require 510(k) clearances and other approvals, so delays or failures in regulatory review could directly block sales of new products. The company also depends on single-source or concentrated suppliers in Asia for critical components, making it vulnerable to shortages, tariffs, shipping disruptions, and geopolitical tension. Because CapsoCloud handles sensitive medical data across jurisdictions, privacy, security, and compliance failures could create legal exposure, delay deployments, and damage customer trust.
- Regulatory clearance delaysImpact: HighLikelihood: High
New products such as CapsoCam Colon and AI-enabled capsules need 510(k) clearance before broad commercialization.
Exposure: Product launch timing and market access
- Reimbursement uncertaintyImpact: HighLikelihood: High
Adoption depends on Medicare and other payors approving adequate reimbursement for the GI-tract solution.
Exposure: Commercial adoption and pricing
- Liquidity and going-concern riskImpact: HighLikelihood: High
The company continues to incur losses and expects to need additional funding to support operations.
Exposure - Supply chain concentrationImpact: HighLikelihood: Medium
Critical components and assembly are concentrated with suppliers in Taiwan and Japan, many of them single-source.
Exposure: Manufacturing continuity and gross margin
- Data privacy and cybersecurity complianceImpact: MediumLikelihood: Low
CapsoCloud must meet country-specific privacy rules and enhanced security requirements for some government customers.
Exposure: International expansion and customer retention
Accounting
Judgemental itemsDifferent timing for product, reading service, and SaaS revenue affects quarterly comparability and reported growth.
Impact: Can shift revenue between periods depending on shipment and service delivery timing
Fees paid to group purchasing organizations are netted against revenue, affecting top-line presentation.
Impact: Reduces reported revenue and can obscure underlying gross demand
Fair value estimates for equity awards rely on Black-Scholes inputs and can materially affect operating expenses.
Impact: Impacts reported losses and dilution analysis
Capsule production requires component purchases, assembly, scrap, freight, and reserve inventory decisions.
Impact: Affects cost of revenue, margins, and working capital
Operating lease payments are a contractual cash obligation and affect balance-sheet and liquidity analysis.
Impact: Relevant to near-term cash needs and fixed-cost structure
Similar listed companies
Publicly listed companies with a comparable business focus.
Capstone Companies, Inc.
CAPC · Electric Lighting & Wiring Equipment
The Cooper Companies, Inc
COO · Ophthalmic Goods
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
VASO Corp
VASO · Electromedical & Electrotherapeutic Apparatus
VASO Corp is a U.S.-based healthcare and information technology company organized around three operating segments: healthcare IT and managed network services,…
Odysight.ai Inc.
ODYS · Services-Computer Integrated Systems Design
Escalon Medical Corp
ESMC · Electromedical & Electrotherapeutic Apparatus
Last updated: 24/09/2026